Cargando…

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer

PURPOSE: Combination of anthracyclines with trastuzumab is hampered by cardiotoxicity. Pegylated liposomal doxorubicin and lapatinib could represent a safer alternative to combination therapy. METHODS: In this phase Ib study with 3 + 3 dose escalation design, patients with HER2-positive advanced bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocca, Andrea, Cecconetto, Lorenzo, Passardi, Alessandro, Melegari, Elisabetta, Andreis, Daniele, Monti, Manuela, Maltoni, Roberta, Sarti, Samanta, Pietri, Elisabetta, Schirone, Alessio, Fabbri, Francesco, Donati, Caterina, Nanni, Oriana, Fedeli, Anna, Faedi, Marina, Amadori, Dino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403877/ https://www.ncbi.nlm.nih.gov/pubmed/28341957 http://dx.doi.org/10.1007/s00280-017-3279-8

Ejemplares similares

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report
por: Maltoni, Roberta, et al.
Publicado: (2020)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
por: Rocca, Andrea, et al.
Publicado: (2018)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients
por: Massa, Ilaria, et al.
Publicado: (2018)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
por: Rocca, Andrea, et al.
Publicado: (2021)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients
por: Scarpi, Emanuela, et al.
Publicado: (2022)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
por: Granato, Anna Maria, et al.
Publicado: (2004)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania
por: Masalu, Nestory, et al.
Publicado: (2017)

Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?
por: Farolfi, Alberto, et al.
Publicado: (2014)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Immune Response in Young Thoroughbred Racehorses under Training
por: Cappelli, Katia, et al.
Publicado: (2020)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

The concomitant use of lapatinib and paracetamol - the risk of interaction
por: Karbownik, Agnieszka, et al.
Publicado: (2018)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Use of Sequential Multiple Assignment Randomized Trials (SMARTs) in oncology: systematic review of published studies
por: Lorenzoni, Giulia, et al.
Publicado: (2022)

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)
por: Hurvitz, Sara, et al.
Publicado: (2018)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer
por: Yi, Huixing, et al.
Publicado: (2021)

Evaluation of Lapatinib-Loaded Microfibers Prepared by Centrifugal Spinning
por: Bitay, Enikő, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_77n03v549aj7a5avh9vl8g2r38